BRCA1相关卵巢癌患者的预后取决于肿瘤细胞中TP53积聚状态
该研究纳入159例高级别卵巢癌患者,评估BRCA1胚系突变相对于TP53积聚状态的临床意义。结果提示TP53积聚状态决定了BRCA1突变携带者的预后:在TP53+亚组中BRCA1携带者复发风险增加(HR 2.25),而在TP53-亚组中BRCA1突变使死亡风险降低46%(HR 0.54,P=0.099,未达统计学显著)。
要点
- 159例高级别卵巢癌中40例(25.2%)为BRCA1胚系突变,102例(64.2%)为TP53+,57例(37.8%)为TP53-。
- TP53+亚组中BRCA1携带者复发风险高于散发病例(HR 2.25,P=0.003),中位无病生存期7.7 vs 18.4个月。
- TP53-亚组中BRCA1突变使死亡风险降低46%(HR 0.54,P=0.099),但未达统计学显著。
核心结论
- 结果提示TP53积聚状态决定了BRCA1突变携带者高级别卵巢癌的预后。
研究设计与样本
- 对159例高级别卵巢癌进行统计分析,采用Kaplan-Meier法、log-rank检验、Cox回归和logistic回归模型,并在TP53+和TP53-亚组中分别分析。
主要发现
- 159例卵巢癌中40例(25.2%)为BRCA1胚系突变,102例(64.2%)为TP53+,57例(37.8%)为TP53-。
- TP53+亚组中BRCA1携带者较散发病例复发风险增加(HR 2.25,P=0.003),中位无病生存期分别为7.7个月 vs 18.4个月。
- TP53-亚组中BRCA1突变使死亡风险降低46%(HR 0.54,P=0.099),中位总生存期分别为42.7个月 vs 28.1个月,但未达统计学显著。
- 不考虑TP53状态时,BRCA1突变无显著意义,但BRCA1突变者较非携带者完全缓解的比值比呈升高趋势(OR 2.47,P=0.064)。
- 紫杉烷-铂类方案在全体患者和TP53+亚组中较铂类-环磷酰胺方案显示优势。
局限性
- TP53-亚组样本量较小(原文称smaller TP53- subgroup)。
- TP53-亚组中BRCA1突变降低死亡风险的HR 0.54,P=0.099,未达统计学显著(beyond the border of significance)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: TP53 mutation is the most frequent molecular event in BRCA1-associated ovarian carcinomas. TP53 status may be a confounding factor in the evaluation of clinical importance of other proteins. We aimed to evaluate the clinical significance of BRCA1 mutations with respect to the TP53 accumulation status in 159 high-grade ovarian carcinomas. METHODS: Statistical analyses were done with the Kaplan-Meier method, log-rank test, the Cox's and logistic regression models for all patients, and in subgroups with and without TP53 accumulation (TP53+ and TP53-, respectively). RESULTS: Forty of 159 ovarian carcinomas (25.2%) were diagnosed in patients with BRCA1 germline mutations; 102 tumors (64.2%) were TP53+ and 57 (37.8%) were TP53-. Among patients with TP53+ carcinomas, BRCA1 carriers had increased odds of recurrence compared with sporadic cases (HR 2.25, P=0.003; median disease-free survival time 7.7 vs. 18.4months, respectively). In the smaller TP53- subgroup, BRCA1 mutation reduced the risk of death by 46% (HR 0.54, P=0.099, median overall survival time 42.7 vs. 28.1months), but beyond the border of significance. When the TP53 status was not taken into account, BRCA1 mutations did not show any significance, however, there was a trend toward increased odds of complete remission for women with BRCA1 mutations compared to non-carriers (OR 2.47, P=0.064). Taxane-platinum therapy showed advantage over the platinum-cyclophosphamide one in the entire group of patients and in the TP53+ subgroup. CONCLUSIONS: Our results suggest that the TP53 accumulation status determines the prognosis of BRCA1 mutation carriers with high-grade ovarian carcinomas.
引用
- Rzepecka IK, Szafron LM, Stys A, et al. Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells. Gynecol Oncol. 2016. PMID: 27939982. doi:10.1016/j.ygyno.2016.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。